Shares of Varex Imaging Corporation (NASDAQ: VREX) experienced a dramatic surge in premarket trading on Monday, climbing 48.3% to $18.40, following the announcement that Teledyne Technologies Incorporated (NYSE: TDY) will acquire the X-ray equipment manufacturer in an all-cash deal valued at approximately $1.1 billion. The offer price of $18.90 per share represents a 52.3% premium over Varex's Friday closing price of $12.41.
The transaction, which has received unanimous approval from the boards of both companies, is expected to close in early 2027, subject to shareholder approval, regulatory clearances, and other customary closing conditions. The deal is structured as a cash tender offer, providing Varex shareholders with a clear and immediate premium.
Investor Implications and Spread Analysis
For investors, the key metric now is the spread between the current trading price and the offer price. With Varex shares trading at $18.40, the $0.50 differential represents a potential gross return of 2.7% if the deal closes at the announced price. However, this return does not account for the time value of money, taxes, or the inherent risks associated with deal completion, including potential regulatory hurdles or shareholder opposition.
The offer price also stands 8.6% above the most recent average analyst target of $17.40, reflecting the substantial premium Teledyne is willing to pay to acquire Varex's specialized technology and market position.
Strategic Rationale and Management Commentary
Teledyne Executive Chairman Robert Mehrabian highlighted a specific strategic gap that Varex fills. "For example, while Teledyne produces X-ray detectors, we do not provide detectors suited for high-radiation environments such as oncology, as does Varex," he stated in the joint announcement. This complementary technology is a key driver of the acquisition.
Varex CEO Sunny Sanyal expressed confidence that Teledyne's extensive resources will accelerate the adoption of Varex's products and expedite the rollout of advanced imaging systems. The combination is expected to create a more comprehensive portfolio in the medical and industrial X-ray imaging sectors.
Varex's Preliminary Fiscal Q3 Results
The acquisition announcement coincided with Varex's preliminary results for its fiscal third quarter, which showed revenue of $210.5 million, a 3.7% increase from $203.0 million in the same period last year. Adjusted gross margin improved by 3.2 percentage points to 36.7%, while non-GAAP diluted earnings per share more than doubled to $0.31, up from $0.13.
The company also reported adjusted EBITDA of $33.1 million, up 20.4% year-over-year. However, a significant portion of the quarter's profitability was boosted by a one-time tariff recovery of $17 million from U.S. Customs, partially offset by a $7 million reserve for potential customer reimbursements. This net $10 million boost to gross profit is unlikely to recur, and investors should be cautious when evaluating the sustainability of these margins.
Segment Performance
- Medical segment: Revenue declined 5.7% to $134.0 million, representing 63.7% of total revenue.
- Industrial segment: Revenue surged 25.6% to $76.5 million, driven by demand from cargo and vehicle inspection systems.
Varex ended the quarter with $99.2 million in cash and marketable securities, down from $155.1 million at the end of the fiscal year, due to debt refinancing and increased inventory levels.
Analyst Reactions and Outlook
The acquisition has rendered previous analyst price targets obsolete. On Monday, Sidoti analyst James Sidoti downgraded Varex to Hold with a $19 price target, closely aligning with the cash offer. Other analysts, including Anderson Schock of B. Riley and Suraj Kalia of Oppenheimer, had previously set targets of $18, which are now below the offer price.
The five-analyst consensus had a $17.40 average target, with ratings ranging from Strong Buy to Hold. These assessments are now largely academic given the cash offer.
Risks and Next Steps
While the deal offers a clear premium, there are inherent risks. The transaction could be delayed or terminated if shareholders or regulators reject it. If the deal falls through, Varex shares would likely revert to pre-announcement levels, as evidenced by Friday's closing price of $12.41. Additionally, the recent margin improvement was partly due to a one-time tariff refund, which may not be repeatable.
Varex has canceled its scheduled earnings call and will not provide forward-looking guidance due to the pending acquisition. Shareholders should await the proxy statement and monitor the regulatory timeline to assess whether the remaining 2.7% spread adequately compensates for the risk of the deal not closing.
